---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Quizartinib Dihydrochloride - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/quizartinib-dihydrochloride
version: v1
---

# Quizartinib Dihydrochloride - NCI

# Quizartinib Dihydrochloride

Placeholder slot

(kwih-ZAR-tih-nib dy-HY-droh-KLOR-ide)

This page contains brief information about quizartinib dihydrochloride
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Vanflyta

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86&audience=consumer)

## Use in Cancer

Quizartinib dihydrochloride
is approved to treat:

- **[Acute myeloid leukemia](/Common/PopUps/popDefinition.aspx?id=46347&version=Patient&language=English)** that is newly diagnosed and has a certain [mutation](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in the *[FLT3](/Common/PopUps/popDefinition.aspx?id=789010&version=Patient&language=English)* gene. It is used in adults, first with [cytarabine](/Common/PopUps/popDefinition.aspx?id=45155&version=Patient&language=English) and an [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=Patient&language=English) drug as [induction therapy](/Common/PopUps/popDefinition.aspx?id=45736&version=Patient&language=English), next with cytarabine as [consolidation therapy](/Common/PopUps/popDefinition.aspx?id=45654&version=Patient&language=English), and then alone as [maintenance therapy](/Common/PopUps/popDefinition.aspx?id=45768&version=Patient&language=English).

Quizartinib dihydrochloride is only available as part of a special program called Vanflyta REMS ([Risk Evaluation and Mitigation Strategies](https://www.vanflytarems.com/#Main)).

## More About Quizartinib Dihydrochloride

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/547019) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Quizartinib Dihydrochloride](https://medlineplus.gov/druginfo/meds/a623034.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients](https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Quizartinib Dihydrochloride](https://www.cancer.gov/research/participate/clinical-trials/intervention/C97272) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
